Rosuvastatin
- Generic Name
- Rosuvastatin
- Brand Names
- Crestor, Ezallor, Roszet
- Drug Type
- Small Molecule
- Chemical Formula
- C22H28FN3O6S
- CAS Number
- 287714-41-4
- Unique Ingredient Identifier
- 413KH5ZJ73
- Background
Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin medications competitively inhibit the e...
- Indication
The FDA monograph states that rosuvastatin is indicated as an adjunct to diet in the treatment of triglyceridemia, Primary Dysbetalipoproteinemia (Type III Hyperlipoproteinemia), and Homozygous Familial Hypercholesterolemia.
...
- Associated Conditions
- Atherosclerosis, Atherosclerotic Cardiovascular Diseases, Cardiovascular Disease (CVD), Cardiovascular Events, Dysbetalipoproteinemia, Heterozygous Familial Hypercholesterolemia (HeFH), High Cholesterol, Homozygous Familial Hypercholesterolaemia (HoFH), Hypertension, Hypertension, Essential Hypertension, Hypertriglyceridemias, Major Adverse Cardiovascular Events, Mixed Dyslipidemias, Postoperative Thromboembolism, Primary Hypercholesterolemia, Primary Hyperlipidemia
- Associated Therapies
- Lipid-Lowering Therapy, Primary Prevention of Cardiovascular Diseases
Efficacy of Lapaquistat Acetate Alone or Combined With Rosuvastatin in Subjects With Hypercholesterolemia
- Conditions
- Interventions
- First Posted Date
- 2005-11-07
- Last Posted Date
- 2012-05-24
- Lead Sponsor
- Takeda
- Target Recruit Count
- 415
- Registration Number
- NCT00249912
DISCOVERY Asia - Crestor in Type IIa and IIb Hypercholesteremia
- Conditions
- First Posted Date
- 2005-10-19
- Last Posted Date
- 2008-02-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1362
- Registration Number
- NCT00241488
A Study to Investigate the Effect of Rosuvastatin (CRESTOR®) on High Density Lipoprotein Kinetics in Patients With the Metabolic Syndrome
- Conditions
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2009-03-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 15
- Registration Number
- NCT00240305
- Locations
- 🇦🇺
Research Site, Perth, Western Australia, Australia
The Effect of Rosuvastatin on Aortic Stiffness in Hemodialysis Patients in the AURORA Study
- Conditions
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2010-11-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 10
- Registration Number
- NCT00240279
- Locations
- 🇳🇱
Research Site, Nieuwegein, Netherlands
Rosuvastatin Impact on Ventricular Remodelling Lipids and Cytokines
- Conditions
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2010-11-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 160
- Registration Number
- NCT00240292
- Locations
- 🇦🇺
Research Site, Perth, Western Australia, Australia
Study of High Density Lipoprotein Cholesterol (HDL-C)-Raising Mechanism of Rosuvastatin (CRESTOR™) by Quantifying the Key Steps of Reverse Cholesterol Transport (RCT)
- Conditions
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2010-11-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 15
- Registration Number
- NCT00240266
- Locations
- 🇦🇺
Research Site, Melbourne, Victoria, Australia
Direct Statin Comparison of LDL-C Values: an Evaluation of Rosuvastatin Therapy
- Conditions
- First Posted Date
- 2005-10-17
- Last Posted Date
- 2010-11-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 824
- Registration Number
- NCT00239330
- Locations
- 🇧🇪
Research Site, Sint-Agatha-Berchem, Belgium
JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events
- Conditions
- Interventions
- First Posted Date
- 2005-10-17
- Last Posted Date
- 2014-03-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 17802
- Registration Number
- NCT00239681
- Locations
- 🇻🇪
Research Site, Punto Fijo, Estado Falcon, Venezuela
Dutch Sub Study: Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA). PET Sub Study
- Conditions
- First Posted Date
- 2005-09-29
- Last Posted Date
- 2010-11-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT00228514
- Locations
- 🇳🇱
Research Site, Groningen, Netherlands
Type III Dysbetalipoproteinemia
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2010-11-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT00214604
- Locations
- 🇿🇦
Research Site, Cape Town, South Africa
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.